PFIZER
Pfizer Inc. is an American multinational pharmaceutical corporation headquartered in New York City. Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than US$1 billion in annual revenues.
Pfizer Limited was listed on the Indian stock exchange in 1966. Today, the company has over one lac shareholders in India. With annual sales of over Rs. 2,000 crores, it is the fourth largest multinational pharmaceutical company in India. The Company has a portfolio of over 150 products across 15 therapeutic areas. Its top brands include Prevenar 13, Lyrica, Corex – DX, Dolonex, Enbrel, Becosules, Gelusil and Folvite among others. In addition to its commercial operations, Pfizer Limited also operates a state-of-the-art, award-winning manufacturing facility in Goa that produces more than a billion tablets annually.
While globally, Pfizer is leading the effort to discover therapeutics and vaccines to counter COVID-19, Pfizer Ltd. is also actively supporting the relief efforts here in India through their Corporate Responsibility platforms. Pfizer Ltd. has deployed an estimated Rs. 2.5 crore towards various COVID-19 relief efforts. Some of the key interventions includes donation of 3 lac protective N95 Masks, providing 5 State-of-the-art ventilators, assisting migrant workers with food relief, COVID-19 treatment facility for police personnel, donated 75,000 essential tablets, supporting quarantine facilities at Dharavi in Mumbai, and donation of 1,00,000 N95 masks.
For the quarter ended 31-03-2021, the company has reported a Consolidated Total Income of Rs 571.96 Crore, which is 6.31% less when compared with last quarter’s Total Income of Rs 608.06 Crore and up by 4.38% from last year same quarter Total Income of Rs 547.43 Crore. Company has reported net profit after tax of Rs 100.55 Crore in latest quarter. The Board of Directors decided to recommend a Final Dividend @ Rs. 35 per equity share of Re. 1/- each for the financial year 2020-21.
The results of Q4 were competent.
